BREAKING: Futures Rise After Volatile, Mixed Market Session Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales. On average, analysts polled by FactSet expected Abbott Laboratories (ABT) to earn $1.30 per share and report $11.39 billion in sales. Leerink Partners analyst Mike Kratky noted strength in the medtech division helped offset weakness in diagnostics, nutrition and established pharmaceuticals. During the y ...

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted earnings per share of $1.30 was in line with consensus estimates, and foreign exchange had a favorable year-over-year impact of 1.4% on third quarter sales [16][17] - Adjusted gross margin was 55.8% of sales, reflecting a decrease due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][17] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [8][9] - Diagnostics saw modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [10][11] - Medical devices experienced a 12.5% sales growth, driven by double-digit growth in diabetes care and cardiac rhythm management [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America grew in the mid-teens [46][47] - In China, the company faced headwinds from VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with overall growth in China around 5% to 7% when excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and easing headwinds from diagnostics [20][25] - Investments in innovation and a robust pipeline are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management, with new product launches like Volt and dual analyte sensors [22][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and new product launches as key growth drivers [20][21] - The company anticipates a recovery in the diagnostics business as headwinds from China moderate and new products are rolled out [48] - Management highlighted the importance of addressing barriers to CGM penetration in the basal segment and emphasized ongoing efforts to increase awareness among primary care physicians [78][80] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, adding over 100 basis points to organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20] Question: U.S. diabetes growth dynamics - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][32] Question: Diagnostics business headwinds - Management acknowledged challenges in the diagnostics segment due to VBP in China but expects a recovery as these headwinds moderate [44][48] Question: Cardiac rhythm management growth - The cardiac rhythm management segment is experiencing significant growth, with expectations for continued market share gains [67][69] Question: Structural heart market outlook - Management is optimistic about the structural heart market, particularly with upcoming product launches and competitive advancements [75][76]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][52] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in the adult nutrition segment [8][9] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets [10] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America experienced mid-teens growth [46] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments remained stable, with a projected growth rate of 5% to 7% excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [20][25] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management [68][69] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [20][21] - The company anticipates a recovery in the diagnostics business, particularly outside of China, and expects to see improved performance in 2026 [48][66] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, enhancing organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on next year's sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20][21] Question: Insights on diabetes growth in the U.S. and internationally - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][31] Question: Updates on the diagnostics business and recovery expectations - Management noted that while challenges remain in China, the diagnostics business outside of China is expected to accelerate, with a recovery anticipated next year [46][48] Question: Performance of the electrophysiology franchise - The electrophysiology segment is experiencing double-digit growth, with positive feedback on new products like the Volt catheter [35][36] Question: Outlook for the cardiac rhythm management market - The dual chamber leadless pacemaker market is expected to grow significantly, with current penetration rates indicating substantial room for growth [68][69] Question: Update on structural heart and left atrial appendage closure - Management is optimistic about future growth in left atrial appendage closure, with new product trials expected to yield positive results [74][75]

ASML and ABT Earnings Reports are in! 🙌⚙️ ASML Holdings (ASML) is a cutting-edge tech giant powering the semiconductor industry with world-leading lithography machines.✅ EPS at €5.49 vs Est €5.38🔴 Revenue at €7.52B vs Est €7.73B🔬 Abbott Laboratories (ABT) is a global healthcare leader driving innovation in diagnostics, medical devices, nutrition, and pharmaceuticals.✅ EPS $1.3 vs Est $1.3🔴 Revenue $11.37B vs Est $11.4B$ASML reaffirms its strong 2030 outlook, while $ABT are well positioned for continued high ...

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5%, excluding COVID test sales, with earnings per share rising to $1.3, reflecting high single-digit growth compared to last year [6][7][18] - Adjusted gross margin was 55.8% of sales, reflecting a decrease due to tariffs, while adjusted operating margin increased by 40 basis points to 23% [19][18] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by adult nutrition, particularly in international markets with a 10% growth [8][9] - Diagnostics experienced modest sales growth, with core lab diagnostics growing 7% excluding China, while point of care diagnostics grew by 8% [10][11] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets [12] - Medical Devices sales grew by 12.5%, with significant contributions from diabetes care and electrophysiology [12][16] Market Data and Key Metrics Changes - International markets for adult nutrition saw a 10% growth, while the U.S. diagnostics market grew by 10% [9][59] - The European diagnostics market grew by 6-7%, and Latin America experienced mid-teens growth [61] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, focusing on new product launches and addressing headwinds in diagnostics [24][27] - Investments in clinical trials and product launches are expected to drive future growth, with a commitment to maintaining a robust pipeline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [22][24] - The company anticipates a recovery in the diagnostics business, particularly outside of China, with expectations for mid to high single-digit growth next year [58][62] Other Important Information - The company is advancing its biosimilar strategy and has made progress in regulatory approvals for several products [12] - The management highlighted the importance of maintaining a full portfolio to drive growth across various segments [50] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting to deliver similar growth rates as in 2025 [22][24] Question: U.S. diabetes growth dynamics - U.S. diabetes care grew by 19%, with expectations for continued strong growth driven by new product launches [32][35] Question: Drivers of diagnostics business recovery - Management noted that while challenges remain in China, growth outside of China is accelerating, with expectations for a recovery in the diagnostics business [58][62] Question: Structural heart market outlook - Management acknowledged the importance of left atrial appendage closure and is optimistic about future growth in this area [96][100] Question: Barriers to CGM penetration in the U.S. - Management identified the need for increased awareness and coverage among primary care physicians as barriers to higher CGM penetration [101][106]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [5][13] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% [14][48] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [6][7] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [7][8] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [8][9] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [9][10] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while the European region saw growth of 6% to 7%, and Latin America grew in the mid-teens [44] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with an overall growth rate of around 5% to 7% when excluding diagnostics [61][62] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [21][22] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned across various businesses [21][23] - The company is focused on expanding its market share in key areas such as diabetes care and electrophysiology, with new product launches like Volt expected to enhance growth [19][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [18][19] - The company anticipates a recovery in the diagnostics business as it laps previous headwinds, with expectations for mid-to-high single-digit growth next year [45] - Management highlighted the importance of adapting to market conditions and maintaining a resilient portfolio to drive growth [19][23] Other Important Information - The company has launched new products that generated nearly half a billion dollars in sales this quarter, contributing significantly to organic sales growth [6] - Regulatory approvals for new medical devices, such as Triclip in Japan and expanded indications for TAVR, are expected to enhance market position [10][11] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting to deliver similar growth rates as in 2025 despite headwinds faced this year [18] Question: Insights on U.S. diabetes market growth - U.S. diabetes care grew by 19%, with expectations for continued strong growth driven by new product launches and increased penetration in the basal segment [26][28] Question: Drivers of ablation catheter growth - Double-digit growth in ablation catheters is driven significantly by international markets, with a strong competitive position in mapping cases [52][53] Question: Outlook for diagnostics business in China - Management expects mid-single-digit growth in China, focusing on expanding contributions from other geographies while navigating current challenges [62] Question: Update on nutrition litigation and market performance - The company remains committed to defending its products amid ongoing litigation, with pockets of softness in nutrition being addressed through strategic investments [80]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key Points Abbott Labs is a well-established medical device giant with a robust, diversified business. The healthcare giant has an incredible innovative streak that has allowed it to remain a leader. Abbott is also a dividend powerhouse, having increased its payout for 53 consecutive years. 10 stocks we like better than Abbott Laboratories › There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn' ...

Core Insights - Abbott reported quarterly earnings of $1.3 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.21 per share a year ago [1] - The company posted revenues of $11.37 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.24%, but up from $10.64 billion year-over-year [2] - Abbott's shares have increased by approximately 17.8% year-to-date, outperforming the S&P 500's gain of 13% [3] Earnings Performance - Over the last four quarters, Abbott has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $1.49, with expected revenues of $11.75 billion, and for the current fiscal year, the estimate is $5.15 on revenues of $44.66 billion [7] Market Outlook - The sustainability of Abbott's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Abbott is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Products industry, to which Abbott belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

格隆汇10月15日｜医疗设备制造商雅培公布第三季度业绩，营收为113.7亿美元，略低于分析师平均预 期的114亿美元；每股收益为1.3美元，符合分析师预期。雅培预计全年每股收益将介于5.12至5.18美元 之间，之前预期为5.1至5.2美元。 ...